Proteome Sciences results in big news CJD + Stroke tests

I also enjoyed 2BOB's reply lbd. I don't think anybody's saying that BSE is not a significant driver of short-term revenues. It depends on what you think of as significant and short-term. 10% / 20% / 50%; 3 months /6 months / 12 months?
I'm fairly certain that BSE will not be the biggest driver of net asset value in 2 years' time. And in the shorter-term, I think the service business eg Sensitiser and Veriq will provide substantial revenues before any of the commercialised tests.

It feels like we're flogging a dead horse now, doesn't it? Lets see what the future brings...